These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 6233994)
1. [Drug surveillance in patients of advanced-age]. Bol Oficina Sanit Panam; 1984 Apr; 96(4):342-52. PubMed ID: 6233994 [No Abstract] [Full Text] [Related]
2. Evaluating drugs after their approval for clinical use. Ray WA; Griffin MR; Avorn J N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139 [No Abstract] [Full Text] [Related]
3. [Critical study of methods of postmarketing drug surveillance]. Gut JP; Auriche M; Spriet-Pourra C; Juillet Y Therapie; 1985; 40(5):313-9. PubMed ID: 3913048 [No Abstract] [Full Text] [Related]
4. Yellow cards and green forms. Inman WH Practitioner; 1983 Sep; 227(1383):1443-9. PubMed ID: 6647229 [No Abstract] [Full Text] [Related]
5. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
6. [Pitfalls of polypharmacy, particularly in the elderly]. Queneau P Bull Mem Acad R Med Belg; 2006; 161(6):408-21; discussion 422-4. PubMed ID: 17288274 [TBL] [Abstract][Full Text] [Related]
7. [Cost/benefit analysis of a regional drug surveillance center]. Mignot G; Chichmanian RM; Spreux A; Bernard G Therapie; 1988; 43(5):377-8. PubMed ID: 3147546 [No Abstract] [Full Text] [Related]
8. [How to report side-effects of drugs?]. Guillaume JC Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239 [No Abstract] [Full Text] [Related]
9. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring]. Goujard J Therapie; 1985; 40(5):287-92. PubMed ID: 4095683 [No Abstract] [Full Text] [Related]
10. [Bayesian approach to the imputability of undesirable phenomena to drugs]. Auriche M Therapie; 1985; 40(5):301-6. PubMed ID: 4095686 [No Abstract] [Full Text] [Related]
11. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period]. Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M Therapie; 1986; 41(5):375-7. PubMed ID: 3810528 [No Abstract] [Full Text] [Related]
12. [A network of regional correspondents for studying undesirable effects]. Haramburu F; Péré JC; Begaud B; Albin H Therapie; 1985; 40(5):321-4. PubMed ID: 4095688 [No Abstract] [Full Text] [Related]
13. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods]. Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H Therapie; 1985; 40(5):307-12. PubMed ID: 4095687 [No Abstract] [Full Text] [Related]
14. New drugs: how to decide which ones to prescribe. Mohler PJ Fam Pract Manag; 2006 Jun; 13(6):33-5. PubMed ID: 16813119 [No Abstract] [Full Text] [Related]
15. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods]. Lagier G; Vincens M; Lefebure B; Frelon JH Therapie; 1983; 38(3):295-302. PubMed ID: 6612666 [No Abstract] [Full Text] [Related]
16. Drug prescribing for the elderly. Lamy PP Bull N Y Acad Med; 1981 Oct; 57(8):718-30. PubMed ID: 6945137 [No Abstract] [Full Text] [Related]
17. Safe and effective drug therapy in older adults. Hume AL Med Health R I; 2005 Jan; 88(1):15-7. PubMed ID: 15779550 [TBL] [Abstract][Full Text] [Related]
18. [Problems of use and preparation of infusion mixtures. 3. Current opinion of the utilization of infusion mixtures in therapy]. Samková M; Malý J Cesk Farm; 1971 Sep; 20(7):269-75. PubMed ID: 4999860 [No Abstract] [Full Text] [Related]
20. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward. Kravitz RL; Bell RA Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573 [No Abstract] [Full Text] [Related] [Next] [New Search]